Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib for AIHA in CLL/SLL/MBL
NCT05694312Phase 2Recruiting
- Sponsor
- GIMEMA
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in autoimmune hemolytic anemia (AIHA), sponsored by GIMEMA. Started Nov 2023; status: recruiting.
02
Drugs
ibrutinib
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT05694312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694312.